Breaking News

Cytovance To Manufacture for Selexys

November 13, 2012

Will supply SelG1 for Phase II trial

Cytovance Biologics has entered an agreement with Selexys Pharmaceuticals to produce its lead asset, an SelG1 monoclonal antibody (mAb) for a Phase II trial in patients with sickle cell disease. Cytovance will lead the cGMP manufacturing along with technical and regulatory support to supply the Selexys clinical program. SelG1 will be manufactured at the 1,000L scale in Cytovance's 44,000-sq.-ft., cGMP production facility.
"Cytovance continues to be an integral part of our efforts at Selexys and has played a key role in the advancement of our clinical programs. We look forward to working with Cytovance on this important project as well as other projects in the future," said Dr. Scott Rollins, president and chief executive officer of Selexys.
"Cytovance shares in Selexys' enthusiasm for the future of SelG1," said Darren Head, president and chief executive officer of Cytovance Biologics. "The recent news and potential of this product, highlighted by the growing partnership between Cytovance and Selexys, is a representation of the well-built biotech community in Oklahoma."

Related Contract Manufacturing:

Related Packaging:

Related Compliance: